Cost-effectiveness analysis of enfortumab vedotin and pembrolizumab versus chemotherapy for patients with untreated advanced urothelial cancer in the United Kingdom
In this economic model analysis, EV-Pem is not cost-effective compared with first-line chemotherapy in the UK, and a price reduction may be necessary.
Authors
- Qiuji Wu (ORCID: https://orcid.org/0000-0002-4655-3108)
- Qiu Li (ORCID: https://orcid.org/0000-0003-3079-1352)
- Yi Qin (ORCID: https://orcid.org/0009-0003-8190-9442)
Institutions
- Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Sichuan Cancer Hospital (CN)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-103709
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- China Postdoctoral Science Foundation